Cathepsin B-specific module, for example, has been successfully implemented for this role, which led to the development of FDA approved therapies; for example, Brentuximab vedotin (Adcetris®) for CD30-positive relapsed or refractory Hodgkin′s lymphoma. This evidence concerns the gene CTSB and Hodgkins lymphoma.